# Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT)

> **NCT01000636** · PHASE4 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 9 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **PROCEDURE:** Metvix PDT

## Key facts

- **NCT ID:** NCT01000636
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01000636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01000636, "Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01000636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*